Immuno-Oncology News

    Skip to content
    • Home
    • Categories
      • Immune Checkpoint Inhibitors
      • T cells
      • PD-1
      • Melanoma
      • Breast Cancer
      • Cancer Vaccines
      • FDA
    • Immuno-Oncology
    • Therapies
      • Approved Drugs
        • Bavencio (Avelumab)
        • Imfinzi (Durvalumab)
        • Keytruda (Pembrolizumab)
        • Kymriah (Tisagenlecleucel)
        • Opdivo (Nivolumab)
        • Tecentriq (atezolizumab)
        • Unituxin (Dinutuximab)
        • Yervoy (Ipilimumab)
        • Yescarta (Axicabtagene Ciloleucel) – Formerly KTE-C19
      • Experimental Therapies
        • a
          • ABBV-181
          • ABBV-428
          • ABP798
          • Actimmune
          • Adagloxad Simolenin
          • ADU-741 (JNJ-64041809 )
          • ADXS-HER2
          • ADXS-PSA
          • AE37
          • AFM11
          • AFM13
          • Zalifrelimab (AGEN1884)
          • Balstilimab (AGEN2034)
          • ALKS 4230
          • AlloStim
          • AM0010 (Pegilodecakin)
          • AMG 211 (MEDI-565)
          • AMG 330
          • AMG 420
          • APVO414 (MOR209/ES414)
          • AST-VAC1
          • ATA520
          • AutoSynVax
        • b-c
          • Idecaptagene Cicleucel (Ide-Cel; Previously bb2121)
          • BGB324 (bemcentinib)
          • Tislelizumab (Previously BGB-A317)
          • Blincyto (blinatumomab)
          • Biropepimut-S (GL-0817)
          • BMS 986178
          • BPX-501
          • BPX-601
          • BriaVax
          • Canakinumab
          • Cavatak (Coxsackievirus – CVA21)
          • CBT-501 (genolimzumab)
          • CBT-502
          • Cergutuzumab Amunaleukin
          • CMP-001
          • CMD-003 (Baltaleucel-T)
          • CRISPR/Cas9 and Cancer
          • CRS-207
          • CS1001
          • CX-072
        • D-F
          • DCVax
          • DI-Leu16-IL2
          • DNX-2401
          • DPX-E7
          • DPX-Survivac
          • Enadenotucirev
          • EP-101 STEMVAC
          • ETBX-011
          • ETBX-021
          • FAZ053
          • Flotetuzumab (MGD006)
        • G-I
          • GALE-301
          • Galinpepimut-S
          • Ganitumab
          • GBR 1342
          • GI-6207
          • GI-6301
          • GL-ONC1
          • Gliovac (ERC1671)
          • GP2
          • GRN-1201
          • GSK3174998
          • GWN323
          • HF10
          • ICT-107
          • ICT-121
          • IGN002
          • IMCgp100
          • IMP701
          • INCAGN1949
          • INO-1400
          • INO-3106
          • INO-5150
          • INO-9012
        • J-L
          • JCAR014
          • JCAR017
          • JNJ-61186372
          • JNJ-63709178
          • JNJ-63723283
          • JNJ-64041757 (ADU-214)
          • JTX-2011
          • KN035
          • LAG525 (IMP701)
          • LAMP-pp65-DC Vaccine
          • Lirilumab (IPH2102/BMS-986015)
          • LOAd703
          • LV305
        • M-O
          • M7824
          • MAGE-A10 T-Cell Therapy
          • MBG453
          • MDNA55
          • MEDI0457
          • MEDI0562
          • MEDI0680
          • MGA012
          • MGD009
          • MK-4166
          • Mogamulizumab
          • MVA-BN Brachyury
          • MVI-118
          • NEO-PV-01
          • NeuVax (Nelipepimut-S)
          • NKR-2
          • NKTR-214
          • NY-ESO TCR
          • OncoVAX
          • ONCOS-102
        • P-S
          • PAN-301-1
          • PDR001
          • PDS0101
          • PF-04518600
          • PF-06801591
          • PNK-007
          • ProscaVax
          • Provenge (Sipuleucel-T)
          • PVRIG
          • REGN2810 (SAR439684)
          • REGN3767
          • Relatlimab
          • Reolysin
          • RG7802
          • RG7828
          • Rocapuldencel-T
          • rSIFN-co
          • SHR-1210
          • SL-701
          • SurVaxM
        • T-Z
          • TT12
          • Tedopi (OSE-2101)
          • Telomelysin (OBP-301)
          • TG4010
          • TPIV 200
          • TPIV200
          • Traumakine
          • TRX518
          • TSR-022
          • TSR-042
          • Utomilumab
          • ValloVax
          • Varlilumab
          • VBI-1901
          • VGX-3100
          • Viagenpumatucel-L
          • Vigil
          • VX15
          • XmAb13676
    • COVID-19 Info
      • COVID-19 Updates

    Resources

    Home » Resources

    • pha
      PH Association
    • nih
      National Institute of Health
    • wiki
      Wikipedia – Pulmonary Hypertension
    • canada
      PH Canada
    • Screen Shot 2014-05-19 at 4.47.55 AM
      American Heart Association
    • drugs
      Drugs.com
    • phcentral
      PH Central
    • knowph
      Know Your PH
    • trials
      Clinical Trials

    Recent Posts

    • Keytruda and SCLC

      Keytruda Will No Longer Treat Advanced Small Cell Lung Cancers in US

      March 5, 2021

    • ilixadencel, cancer vaccine, update

      Ilixadencel-Sutent Combo Shows ‘Meaningful’ Survival in Advanced Kidney Cancer Patients

      March 3, 2021

    • Imfinzi, advanced bladder cancer

      Imfinzi No Longer Available in US for Advanced Bladder Cancer

      March 1, 2021

    Featured Posts

    FDA Approves Bavencio Maintenance Therapy for Advanced Bladder Cancer

    July 2, 2020

    Bavencio approval

    FDA Approves Keytruda as First-line Therapy for Certain Advanced Colorectal Cancers

    July 1, 2020

    Health Canada approves Opdivo-Yervoy-chemo for metastatic NSCLC

    FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

    June 30, 2020

    Keytruda and SCLC
    Visit Immuno-Oncology News's profile on Pinterest.
    Bionews, Inc.
    3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363
    • Publishing Team
    • Leadership
    • Our Values
    • Corrections Policy
    • Contact Us
    • Terms of Service
    • Privacy Policy

    Disclaimer:

    Immuno-Oncology News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
    Copyright © 2013-2025 All rights reserved.